Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitiglinide/voglibose - Kissei Pharmaceutical/Takeda

Drug Profile

Mitiglinide/voglibose - Kissei Pharmaceutical/Takeda

Alternative Names: Glubes; KMV-0207; Voglibose/mitiglinide

Latest Information Update: 17 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kissei Pharmaceutical; Takeda
  • Class Inositol phosphates; Isoindoles; Small molecules; Sugar alcohols
  • Mechanism of Action Alpha-glucosidase inhibitors; Insulinotropin agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 14 Jun 2019 Launched for Type 2 diabetes mellitus (rapidly disintegrating oral formulation) in Japan
  • 30 Jan 2019 Chemical structure information added
  • 20 Aug 2018 Kissei Pharmaceutical terminates a clinical trial in Type-2 diabetes mellitus in Japan (UMIN000026185)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top